Trials / Completed
CompletedNCT00495339
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB. Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levofloxacin | 500-1000 mg once a day daily per os with combination of drugs. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-04-01
- First posted
- 2007-07-03
- Last updated
- 2009-03-04
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT00495339. Inclusion in this directory is not an endorsement.